BriaCell spins off sCD80 cancer therapy to BriaPro in strategic deal

FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients

The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy

Merck, Mayo Clinic forge AI powerhouse to accelerate drug discovery

FDA refuses to file Moderna’s seasonal flu vaccine application, citing comparator issue

The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”

Moderna signs five-year strategic mRNA vaccine pact with Mexico

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security

Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

Time Medical India unveils next-generation MRI platforms at IRIA 2026

The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology

Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26

The revenues this quarter are in line with the outlook we envisaged for the year

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating